The OPTiM multicenter phase III trial conducted by Andtbacka et al. [17] randomized 436 patients with unresected stage IIIB, IIIC, and IV melanoma to either intratumoral injection with T-VEC or subcutaneous recombinant GM-CSF. Here, CSF2 is linked to melanoma.